# Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation

> **NCT03423030** · PHASE1 · COMPLETED · sponsor: **Innovative Medicines for Tuberculosis** · enrollment: 32 (actual)

## Conditions studied

- Tuberculosis
- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** PBTZ169 Formulation
- **DRUG:** Placebo
- **DRUG:** PBTZ169 NCP

## Key facts

- **NCT ID:** NCT03423030
- **Lead sponsor:** Innovative Medicines for Tuberculosis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-05
- **Primary completion:** 2018-03-28
- **Final completion:** 2018-03-28
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03423030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03423030, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03423030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*